HER2 弱陽性(HER2-low)乳癌新分類:trastuzumab deruxtecan 的擴展與後續挑戰
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Lenguaje: | chino |
| Publicado: |
Zenodo
2026
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866901562596524032 |
|---|---|
| author | Lin, Hsieh-Ting |
| author_facet | Lin, Hsieh-Ting |
| contents | <p>DESTINY-Breast04 (2022) 確立 trastuzumab deruxtecan 於 HER2-low 第二線;DESTINY-Breast06 (2024) 進一步擴展至 HR+ 內分泌治療後、尚未化療的族群。本文整理 HER2-low 定義、流行病學、IHC 判讀一致性、ILD 監測與 NCCN v3.2026 的新分層。</p><p><strong>線上閱讀:</strong><a href="https://lin.hsiehting.com/posts/2026/her2-low-breast-cancer">https://lin.hsiehting.com/posts/2026/her2-low-breast-cancer</a></p><p><strong>主題:</strong>HER2 低度表現乳癌 (HER2-low breast cancer)</p><p><strong>審稿醫師:</strong>林協霆(MD, 內科專科醫師, 腫瘤內科)<br><strong>審稿日期:</strong>2026-05-11</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20115186 |
| institution | Zenodo |
| language | zho |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | HER2 弱陽性(HER2-low)乳癌新分類:trastuzumab deruxtecan 的擴展與後續挑戰 Lin, Hsieh-Ting 乳癌 HER2-low trastuzumab deruxtecan T-DXd DESTINY-Breast 衛教 <p>DESTINY-Breast04 (2022) 確立 trastuzumab deruxtecan 於 HER2-low 第二線;DESTINY-Breast06 (2024) 進一步擴展至 HR+ 內分泌治療後、尚未化療的族群。本文整理 HER2-low 定義、流行病學、IHC 判讀一致性、ILD 監測與 NCCN v3.2026 的新分層。</p><p><strong>線上閱讀:</strong><a href="https://lin.hsiehting.com/posts/2026/her2-low-breast-cancer">https://lin.hsiehting.com/posts/2026/her2-low-breast-cancer</a></p><p><strong>主題:</strong>HER2 低度表現乳癌 (HER2-low breast cancer)</p><p><strong>審稿醫師:</strong>林協霆(MD, 內科專科醫師, 腫瘤內科)<br><strong>審稿日期:</strong>2026-05-11</p> |
| title | HER2 弱陽性(HER2-low)乳癌新分類:trastuzumab deruxtecan 的擴展與後續挑戰 |
| topic | 乳癌 HER2-low trastuzumab deruxtecan T-DXd DESTINY-Breast 衛教 |
| url | https://doi.org/10.5281/zenodo.20115186 |